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ABSTRACT
The antigenic makeup of tumour cells can have a profound effect on the progression of cancer and
success of immunotherapies. Therefore, one strategy to improve the efﬁcacy of cancer treatments is to
augment the antigens displayed by tumours. The present study explores how the recognition of tumour
cells may be altered by non-cytotoxic concentrations of gemcitabine (GEM). Testing a panel of
chemotherapeutics in human cancer cell lines in vitro, it was found that GEM increased surface expression
of HLA-A,B,C and that underlying this were speciﬁc increases in b-2-microglobulin and
immunoproteasome subunit proteins. Furthermore, the peptide antigen repertoire displayed on HLA class
I was altered, revealing a number of novel antigens, many of which that were derived from proteins
involved in the DNA-damage response. Changes in the nature of the peptide antigens eluted from HLA-A,
B,C after GEM treatment consisted of amino acid anchor-residue modiﬁcations and changes in peptide
length which rendered peptides likely to favour alternative HLA-alleles and increased their predicted
immunogenicity. Signalling through the MAPK/ERK and NFkB/RelB pathways was associated with these
changes. These data may explain observations made in previous in vivo studies, advise as to which
antigens should be used in future vaccination protocols and reinforce the idea that chemotherapy and
immunotherapy could be used in combination.
Introduction
The recognition of antigenic molecules on the surface of
tumour cells plays an important role in CD8C T-cell-mediated
clearance of cancer. Part of this recognition is dependent
upon the MHC class I-antigen complex which indicates the
health of the cell by displaying signs of aberrant protein expres-
sion to the immune system. Loss of MHC class I can hide
tumour cells from the adaptive immune response, preventing
detection by removing antigenic evidence of cancer-related
proteins from the plasma membrane. HLA class I downregula-
tion has been observed in numerous human tumour types,1-4
and can be mediated through defects in a-heavy chain or b-2-
microglobulin (b2 m).5,6 Downregulation of MHC class I is
strongly associated with poor prognosis in cancer,7-9 and so
reversing this is a promising strategy to enhance or reengage an
anti-cancer immune response, especially in cancers character-
ised by low MHC class I, such as colorectal cancer.10 MHC class
I expression has been shown to be increased on tumour cells in
response to stress stimuli, including chemotherapeutic treat-
ments such as 5-ﬂuoracil (5-FU) and gemcitabine (GEM).11,12
In addition to the absolute level of MHC class I, the peptide
antigens expressed in conjunction with MHC class I are vital in
the detection of cancer by immune cells and as such, antigen-
speciﬁc tumour immunotherapy will be enhanced by the iden-
tiﬁcation of putative tumour-associated immunogenic HLA-
ligands. Many factors inﬂuence the make-up of these peptide
ligands but an important part of this process is the cleavage of
peptide bonds which can be catalysed by constitutively
expressed proteasomal subunits or the interferon
(IFN)-g-inducible immunoproteasomal subunits LMP2 (b1i),
MECL-1 (b2i) and LMP7 (b5i).13,14 Compared with their con-
stitutively expressed counterparts, immunoproteasomal subu-
nits confer increased trypsin and chymotrypsin-like activity
and generate peptides with distinctive C-termini.15-17
GEM is a nucleoside analogue that has a broad spectrum of
anti-tumour activity against solid tumours, it exerts its antipro-
liferative effects via “masked-termination” of DNA replication
and targeting of ribonucleotide reductase, an enzyme required
for DNA replication and repair.18 GEM has been successfully
combined with a number of different immunotherapies in can-
cer. It is reported that GEM improves dendritic cell (DC) vacci-
nation in clinical and pre-clinical settings, possibly by
encouraging a cytotoxic T-cell response against subdominant
immune epitopes.19-23 GEM selectively removes myeloid-
derived suppressor cells (MDSC) in mice;24,25and this may link
to the potentiation of immunotherapy that is observed in
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combination with GEM. However, this has not been extensively
studied in humans where there are conﬂicting reports on the
ability of treatments involving GEM to reduce the percentage
of Lin¡DR¡CD11bC MDSC in patients with advanced adeno-
carcinoma.26 GEM is not associated with suppression of lym-
phatic activity in cancer patients,27-29 and is shown to expand
the T-lymphocyte subset and increase tumour inﬁltration in
mice by enhancing cross-priming of tumour-speciﬁc CD8C T-
cells.30 Additionally, GEM increases the absolute numbers and
percentage of peripheral CD14C monocytes and DCs in pan-
creatic cancer patients,31 and in mice broadens the range of
tumour antigens seen by CD8C T-cells by shifting the CD8C T-
cell response towards subdominant epitopes.32
Considering the capacity of GEM to upregulate MHC class I
on the surface of tumour cells in in vitro and in vivo settings;12
and the coordinated regulation of MHC class I and the antigen
processing machinery (APM), we suggested that in addition to
inﬂuencing MHC class I expression, other changes in antigen
presentation may be caused GEM. In the present study we con-
ﬁrm GEM-mediated upregulation of cell surface HLA-A,B,C
and demonstrate that this is inﬂuenced by altered expression of
b2 m. Moreover, consistent with our hypothesis, GEM also
induced upregulation of immunoproteasomal subunits and
altered the peptide antigens displayed by tumour cells in in
vitro cell cultures.
Results
GEM altered expression of HLA-A,B,C at the surface of
tumour cells
Surface expression of HLA-A,B,C was measured on a panel of
tumour cell lines after culturing with equi-active concentrations
of chemotherapeutic drugs for 24 hours. Representative plots
are shown in Fig. 1a. GEM signiﬁcantly increased expression of
HLA-A,B,C in all three cell lines (Fig. 1b). The mean change in
HLA-A,B,C expression in response to culture with GEM, as
measured by a change in MFI from untreated controls, was
81.3% for HCT116 cells, 67.7% for A549 cells and 41.5% for
MCF-7 cells. For comparison, 1000 IU/ml IFNg increased
HLA-A,B,C by 62.2% in HCT116 cells, 142.9% in A549 cells
and 367% in MCF-7 cells (data not shown). Cyclophosphamide
(CPM) did not inﬂuence HLA-A,B,C expression while oxalipla-
tin (OXP) had no effect on expression of HLA-A,B,C in A549
and HCT116 cells but reduced expression in MCF-7 cells by
24.8%. Increased surface expression of HLA-A,B,C was
Figure 1. GEM increased HLA class I expression on tumour cells in a b2 m-associated manner. a) Representative histograms showing change in HLA-A,B,C MFI in response
to culture with drugs at IC25. b) The effect of chemotherapy drugs on surface expression of HLA-A,B,C on tumour cells as measured by ﬂow cytometry. Data are expressed
relative to untreated controls. Mean and standard deviation is plotted and values are signiﬁcantly different ( D p<0.0001,  D p<0.01) to controls by one-way
ANOVA with Dunnett’s multiple comparisons test. n D 3. c) Blots representative of three experiments showing expression of HLA a-heavy chains and b2 m proteins in
untreated (Un), IFNg-treated (1000 IU/ml) or GEM-treated (100 nM) tumour cells. d) Transcription of the b2 m gene was increased in HCT116 cells in response to GEM, as
assessed by qPCR. nD 1. e) Mean fold-change in mRNA for HLA class I genes in response to GEM. nD 3. f) Tumour cells transfected with human b2 m expressing plasmid
had increased surface expression of HLA class I 48 hours after transfection, as measured by ﬂow cytometry. Means and standard deviations are plotted and mock-trans-
fected and b2 m-transfected are signiﬁcantly different by student’s paired t-test. For A549 and MCF-7, n D 3, for HCT116 nD 6.
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associated with increased levels of intracellular b2 m but not
a-heavy chain proteins. Western blots showed that the amount
of b2 m protein detected increased in response to GEM in all
three cell lines (Fig. 1c). In contrast expression of HLA class I
a-heavy chains A, B and C were not altered by GEM treatment.
Real-time PCR and microarray data, performed only on
HCT116 cells (Fig. 1d and e), suggested that the increase in
b2 m may be partially due to increased gene transcription.
These gene analyses also corroboratively indicated that a-heavy
chain expression remained unchanged by culturing with GEM.
Transfection of A549, HCT116 and MCF-7 cells with a b2 m-
expressing plasmid was sufﬁcient to increase surface expression
of HLA-A,B,C (Fig. 1f). Generally, transfected cells displayed a
smaller increase in HLA-class I compared to GEM-treated cells.
Immunoproteasome subunits are expressed upon
treatment with GEM
In addition to changes in HLA-A,B,C, expression of the immu-
noproteasome catalytic subunits LMP2 and MECL-1 was also
induced by GEM in all three cell lines (Fig. 2a). Expression of
the third immunoproteasome subunit, LMP7, was not detect-
ably increased at this concentration and time-point.
Proteasome pull-outs from HCT116 cells showed that LMP2
and MECL-1 were incorporated into proteasomes in increasing
amounts after GEM treatment. Fig. 2b shows expression of the
constitutive proteasome subunits b1, b2 and b5, the immuno-
proteasome subunits LMP2, LMP7 and MECL-1, and a2,
which is present in both forms of proteasome, in control and
HCT116 cells treated with GEM for 24 hours. Shown are the
relative amounts of each protein in crude cell lysate, unbound
and proteasomal fractions. LMP2 and MECL-1 coimmunopre-
cipitated with proteasomes in GEM-treated cells, LMP7 was
also present in this fraction. Subunit a2 was used as a loading
control, indicating the total amount of proteasome present.
There was little change in the expression of the constitutive
proteasome subunits, b1, b2 and b5 in the crude lysate or pro-
teasomal fractions.
The types of peptides displayed on HLA-A,B,C are altered
by GEM
The induction of LMP2 and MECL-1 in tumour cells in
response to culture with GEM suggests that there may also be
changes to the HLA-expressed peptidome of these cells. To
assess this, HCT116 cells were cultured alone or with GEM and
peptides eluted from HLA-A,B,C molecules before being
sequenced by mass spectrometry. The sequences derived were
analysed by comparing the peptide antigens present only on
the surface of the GEM-treated cells versus those found on only
control cells.
In the presence of GEM, the peptide repertoire displayed on
the surface of tumour cells was altered. There was a noticeable
change in the length of peptides, with 8-mers making up 9.8%
of peptides exclusively displayed on control cells but 17.1% of
peptides exclusively displayed on GEM-treated cells. In addi-
tion, there were fewer peptides with a length of 10 amino acids
or more after GEM treatment (26.2% versus 16.1%) (Fig. 3a).
GEM also increased the proportion of leucine and phenylala-
nine residues at the C-terminus of the peptide sequences
(Fig. 3b). Of the peptides that appeared only on control cells,
7.6% had C-terminal leucine. For peptides that appeared only
after GEM treatment, this was increased to 12.2%. The propor-
tion of phenylalanine residues at the C-terminus was increased
to an even greater extent after GEM-treatment, from 2.2% to
8.0% and this change reached statistical signiﬁcance. Con-
versely, after treatment with GEM the numbers of peptides
with alanine or proline at the C-terminus was decreased, from
27.8% to 13.2% and 10.1% to 5.0%, respectively, the latter
reaching statistical signiﬁcance.
HLA-binding preferences for individual peptides were ana-
lysed using HLA binding prediction servers IEDB analysis
resource and SYFPEITHI. The percentage of peptides predicted
to bind most strongly to HLA-B18:01 was larger in the GEM-
treated group than the untreated group (Fig. 3c). On average,
10.6% of peptides were predicted to bind to HLA-B18:01 in
control cells but this was increased to 24.9% in GEM-treated
cells. Conversely, the percentage of peptides predicted to bind
most strongly to HLA-B45:01 decreased from 38.7% in control
cells to 18.7% in GEM-treated cells. This preference for pepti-
des to bind HLA-B18:01 after GEM was underpinned by
changes in the anchor residues occurring at binding position
Figure 2. GEM induced immunoproteasome subunits in tumour cells. a) Immuno-
proteasome expression was assessed by Western blot after 24 hour culture with
100 nM GEM. IFNg (1000 IU/ml) was used as a positive control. Blots are represen-
tative of three separate experiments. b) Proteasomes were isolated from HCT116
cells either untreated (Un) or treated with 100 nM GEM (G) for 24 hours. Expression
of proteasome and immunoproteasome subunits in crude cell lysate, unbound and
proteasome pull-out fractions was then measured. Representative blots from three
separate experiments are shown.
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P2 and was especially true for peptides with an F or L residue at
the C-terminal position which were now more likely to be asso-
ciated with an acidic amino acid at the P2 position (Supple-
mental Figure S1). A prediction model was used to assess the
immunogenicity of the eluted peptides.33 Peptides displayed on
HLA class I exclusively after culture with GEM were, on aver-
age, predicted to be more immunogenic than those peptides
found on control cells (Fig. 3d).
GEM treatment causes new protein representation in the
peptidome
Eluted peptides were used to identify proteins expressed in
HCT116 cells and then we asked whether new epitopes were
generated from within these proteins in the presence of GEM.
Table 1 lists a sample of proteins from which the peptidome of
HCT116 cells was derived. Only proteins with novel GEM-
exclusive peptides found in at least two of three peptide elution
experiments are shown.
The peptide SEQETLVRP from the oncoprotein Mdm2, was
found before and after GEM treatment. However, after cells
were cultured with GEM, additional peptides from Mdm2 were
also detected in the immunopeptidome of HCT116 cells:
DEVYQVTVY, YTMKEVLFY and DEKQQHIVY. Using pep-
tide spectral matches (PSMs) as a measure of abundance,
SEQETLVRP made up 0.26% of peptides eluted from control
cells but 0.56% in GEM-treated cells (Fig. 4a). Intracellular
expression of MDM2 remained unchanged by GEM treatment
(Fig. 4c), though transcription may have increased, 144.1 versus
207.5 units, measured by microarray.
The presentation of new antigens to the immune system was
also observed with other proteins, including DNA Topoisomer-
ase 1 (TOPO1). Expression of TOPO1 decreased slightly in the
presence of GEM, as assessed by microarray (390.7 versus
365.5) and Western blot (Fig. 4c), but an additional peptide,
YLDPRITVA, was generated in GEM-treated cells (Table 1).
Interestingly, in control cells peptides from TOPO1 made up
only 0.013% of total peptides but with GEM treatment this was
increased nearly tenfold to 0.11% (Fig. 4a). These data imply
that expression level alone does not drive the appearance of
new epitopes within individual proteins. As well as an increas-
ing diversity of peptides from a particular protein, peptide anti-
gens from proteins not represented on HLA-A,B,C at the
surface of control HCT116 cells also appeared after culturing
cells with GEM. For example, the lung cancer oncoprotein,
kanadaptin, was not represented in the immunopeptidome of
HCT116 cells under basal conditions, however, upon culture
with GEM the peptide EENPIVLEF was displayed on HLA
class I (Table 1). No peptide exclusive to GEM treatment was
found in all three peptide elution experiments.
However, there were 31 peptide sequences present on both
control and GEM-treated HCT116 cells that were conserved
between all three experimental repeats. The relative fold-change
in the abundance of these peptides in response to GEM (as
measured by changes in PSMs) is shown in Fig. 4b. Two pepti-
des showed a fold-difference greater than two and were
Figure 3. Peptide ligands eluted from HLA-A,B,C on HCT116 cells treated with 100 nM GEM were different from those found on untreated control cells. All panels repre-
sent mean and standard deviation values of three separate peptide elution experiments and show differences in the proportion of peptides with various characteristics
between those found exclusively on treated or exclusively on control cells in terms of: a) Peptide length, b) C-terminal amino acid, c) Predicted HLA-allele binding, d) Pre-
dicted immunogenicity. Values signiﬁcant different from controls by student’s t-test are indicated ( D p<0.01). Due to the anomalous appearance of a number of 11
and 12mer peptides in one of the three peptide elution experiments, data from this particular experiment was removed from the analysis of a) and replaced by peptide
length data from a small pilot study.
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statistically different from no change, NTDSPLRY, from 40 S
ribosomal protein SA, which was downregulated in response to
GEM treatment, and IADMGHLKY, from the protein prolifer-
ating cell nuclear antigen (PCNA), which was upregulated. The
intracellular expression of PCNA was unchanged by GEM
treatment (Fig. 4c).
Of the proteins measured by Western blot, only RPA70
showed major changes in expression in response to GEM treat-
ment (Fig. 4c). The loss of RPA70 protein alongside increases
in the amount of RPA70 peptides at the surface of the cell upon
GEM treatment may suggest increased degradation of this pro-
tein as part of the response to GEM.
Table 2 lists the peptides found exclusively after GEM treat-
ment in more than one of the peptide elution experiments.
References to these sequences were then investigated in the sci-
entiﬁc literature. Of 86 GEM-speciﬁc peptides conserved
between two experiments, 53 (61.63%) were novel (no reference
could be found), whereas 33 had been reported previously.
MEK and NFkB are involved in GEM mediated HLA-A,B,C
upregulation
In accordance with previous reports, culturing tumour cells with
GEM was found to activate the MEK signalling pathway,
increasing phosphorylation of ERK1/2 (Fig. 5a). To test whether
this was involved in upregulation of HLA-A,B,C and the changes
in the peptide repertoire, phosphorylation of ERK1/2 was inhib-
ited by U0126 in GEM-treated HCT116 cells and the effect on
HLA-A,B,C surface expression and intracellular LMP2 mea-
sured. Inhibition of ERK1/2 phosphorylation was demonstrable
by Western blot (Fig. 5d) and reduced GEM-induced HLA-A,B,
C in a dose-dependent manner (Fig. 5b). GEM alone increased
expression of HLA-A,B,C by a mean of 78% compared to
matched untreated control but this was reduced to 57% when
1 mM U0126 was added to the culture medium and 23% at
10 mM of U0126. It should be noted that treatment with U0126
alone did increase basal expression of HLA-A,B,C.
Western blots showed that GEM-mediated LMP2 upregula-
tion was also reduced when inhibiting phosphorylation of
ERK1/2 (Fig. 5c and d). GEM alone increased relative expres-
sion of LMP2 1.8-fold above untreated controls, however, this
was reduced to 1.3-fold and to basal levels by 1 mM and 10 mM
U0126, respectively. As with HLA-A,B,C, use of the MEK
inhibitor alone was associated with increased LMP2 (Fig. 5d).
In addition to the MEK pathway, NFkB was also involved in
GEM-mediated HLA-A,B,C upregulation. Culture with GEM
caused nuclear translocation of the NFkB subunits RelB and p52
in HCT116 cells. No effect on the p65 subunit of NFkB was
observed (data not shown). The involvement of NFkB in GEM-
mediated HLA-A,B,C upregulation was conﬁrmed by inhibiting
NFkB with IKK-16. Expression of HLA-A,B,C was reduced from
a mean MFI of 3288 units with GEM alone to 1698 units with
2.5 mM IKK-16 also present. These data suggest that GEM acti-
vates non-canonical NFkB signalling and that this is important
in the regulation of HLA-A,B,C at the surface of tumour cells.
Discussion
In this study it was found that the chemotherapeutic drug, GEM,
increased expression of HLA-A,B,C on the surface of a number
Figure 4. GEM alters the immunopeptidome of tumour cells. a) Relative abundance of peptides from MDM2, RPA70 and TOPO1 proteins was assessed in control and
GEM-treated HCT116 cells. n D 2. b) The relative abundance of all peptides present in both control and GEM treated cells in all three experiments is shown. Values signiﬁ-
cantly different from controls by student’s paired t-test are indicated ( D p<0.05). c) Western blots showing the expression of proteins that have an altered peptide
representation in GEM-treated cells are shown. Blots are representative of three separate experiments.
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of different tumour cell lines. This upregulation occurred using
low concentrations of GEM and was associated with increased
levels of b2 m. Moreover, this study demonstrated that GEM
induced immunoproteasome subunit expression and that this
corresponded to changes in the immunopeptidome of HCT116
cells, which included the display of novel potential T-cell epito-
pes not present on control cells.
MHC class I is often down-modulated in tumour cells,
rendering them less susceptible to CD8C T-cell-mediated
killing, and it is presently unclear whether the changes in
HLA-A,B,C observed in response to GEM represent an
increase above basal levels or some correction of previous
downregulation. However, culturing cell lines with GEM
upregulated b2 m but not a-heavy chain expression and
reduction of MHC class I expression in cancer frequently
occurs through defects in b2 m which are often revers-
ible.34,35 It is interesting to note that transfection with b2 m
protein alone was able to increase HLA-A,B,C at the surface
of the tumour cells tested here. Because of the role of b2 m
in the MHC class I folding, mutation of the b2 m gene leads
to the gradual loss of HLA class I and immune escape during
tumour progression.36 b2 m deﬁciency, through mutation or
other means, is reported in a number of cancer types37-39
and is proposed as a reason for the failure of check-point
blockade therapy.40 Our data demonstrate that through mod-
ulation of b2 m, GEM increases MHC class I expression,
suggesting the potential to correct non-mutational MHC
class I deﬁciency in tumour cells by using GEM.
MHC class I expression increases in response to various che-
motherapy drugs and radiation.11,12,41,42 This may form part of
a normal stress response and represents an increase in the
quantity of the MHC class I-antigen complex on the surface of
tumours. Increasing the number of antigens on a tumour cell
is, on balance, a good strategy to elicit an immune response
against tumour. However, what may be equally or even
more important than the quantity of the antigens presented, is
the quality of the antigens and a major ﬁnding of the present
study is that culturing with GEM altered the nature of peptide
antigens displayed on HLA class I by tumour cells.
Exposure to 100 nM GEM increased expression of the
immunoproteasomal subunits LMP2 and MECL-1 in tumour
cells and these proteins were detected in proteasomes using a4
pull-outs. No increases were found in the total amount of
LMP7 present in tumour cells in response to GEM, though
LMP7 was found in proteasomes. Proteasomes can exist as con-
stitutive, mixed, or immunoproteasomes, dependent on which
catalytic subunits are present and so the precise composition of
proteasomes in GEM-treated HCT116 cells is not currently
known. However, the induction of immunoproteasomal subu-
nits by GEM suggests an alteration in the way in which proteins
are degraded and may help explain the new pattern of peptides
within the tumour cell immunopeptidome.43 It is suggested
that immunoproteasomally cleaved peptides may be distin-
guished by their tendency to have particular hydrophobic
amino acids, such as phenylalanine or leucine, at the C-termi-
nus.44-46 Data presented in the present study also indicate an
increase in the proportion of peptides with phenylalanine or
leucine at the C-terminus eluted from HLA-A,B,C after culture
with GEM. An interesting further study would be to compare
the peptide antigens eluted from GEM-treated cells to
Table 1. How proteins were represented in the immunopeptidome of HCT116 cells was altered by GEM, which induced new peptide antigens from proteins which were
displayed on HLA-A,B,C. In addition to proteins having altered peptide representation after GEM treatment, new proteins were also represented in the immunopeptidome
of HCT116 cells after GEM treatment. Microarray data is also shown indicating the relative amount of mRNA present for each gene. A sample of proteins with consistently
expressed GEM-novel peptides in at least two peptide elution experiments are shown.
Protein
Peptide(s)
from Control
Peptide(s)
from Treated
Microarray
score Control
Microarray
score Treated
Oncoprotein Mdm2 SEQETLVRP SEQETLVRP 144.1 207.5
DEVYQVTVY
YTMKEVLFY
DEKQQHIVY
Replication protein A 70 kDa DNA-binding subunit AEAILGQNAA AEAILGQNAA 2977.9 3072.2
DTEFPNFKY DTEFPNFKY
TEFPNFKY
Pyruvate dehydrogenase [acetyl-transferring]]-phosphatase 1 VGDPNSFLNY VGDPNSFLNY 1672.9 1389.5
SLLPHETLL
DNA Topoisomerase 1 SQIEADFRL SQIEADFRL 390.7 365.5
YLDPRITVA
Cullin-9 LLLDLERVL 189.4 211.8
Kanadaptin EENPIVLEF 255.8 226.8
Serine/threonine-protein kinase PLK2 NEDRISTTF 235.9 246.3
Exosome component 10 DEYDFYRSF 1608.8 1580.5
Spermatogenesis-associated serine-rich protein 2 SSEKGGMNGY 864.9 715.0
Dynamin-2 TLIDLPGITKV 292.8 286.8
ETERIVTTY
Antigen peptide transporter 1 (TAP 1) LLYESPERY 726.0 1235.8
Sestrin-1 SLAELVHAV 212.0 639.4
QMDGPLPLHY
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Table 2. References to the sequences of peptides exclusive to GEM treatment and conserved in two of three experiments were searched for in the scientiﬁc literature.
“Novel“ indicates that the present study is the ﬁrst time the peptide has been reported. Otherwise, peptides found previously in: A D Patent - Cytotoxic T-lymphocyte-
inducing immunogens for prevention treatment and diagnosis of cancer,56 BD Patent - Comparative ligand mapping from MHC class I positive cells,57 C D Toward a Def-
inition of Self: Proteomic Evaluation of the Class I Peptide Repertoire,58 D D Characterization of spontaneous tumor antigen-reactive T cell responses in melanoma
patients and treatment of human melanoma with optimized T cell receptor transgenic T cells in a xenotransplantation model,59 E D Patent - MHC molecule-binding
tumor-associated peptides,60 F D Features of TAP-independent MHC class I ligands revealed by quantitative mass spectrometry.61 IEDB D Found in the immune epitope
database.
Peptide Protein Description
1 LSLENLEKI Phosphatidylinositide phosphatase SAC2 A (2008)
2 NEDRISTTF Serine/threonine-protein kinase PLK2 Novel
3 DEYDFYRSF Exosome component 10. B and C
4 SLAELVHAV p53 regulated PA26 nuclear protein Known immune epitope IEDB
5 DEFEFLEKA E3 ubiquitin/ISG15 ligase TRIM25 B and C
6 DEVYQVTVY E3 ubiquitin-protein ligase Mdm2 B and known CLL ligand
7 YTMKEVLFY E3 ubiquitin-protein ligase Mdm2 Novel
8 DEGLIIHVF Protein kinase C, zeta Novel
9 SSEKGGMNGY Spermatogenesis-associated serine-rich protein 2 Novel
10 VVEQLKDWLY MAD2 mitotic arrest deﬁcient-like 1 Novel
11 MEVEVDGQKF Interleukin enhancer-binding factor 3 Known immune epitope IEDB
12 SEIELFRVF U5 small nuclear ribonucleoprotein 200 kDa helicase known immune epitope IEDB and A
13 TLWVDPYEV B-cell Translocation Gene 1 Known immune epitope IEDB
14 NEAIMHQY Protein FAM111B Novel
15 MEQVIFKY ARP3 actin-related protein 3 homolog; B
16 ETERIVTTY Dynamin 2 Novel
17 NQVIFPVSY Mak3 homolog Known immune epitope IEDB
18 EENPIVLEF Kanadaptin Known immune epitope IEDB
19 LTEIKGSVY Zinc ﬁnger with UFM1-speciﬁc peptidase domain protein Novel
20 ADKVHLMY E3 ubiquitin/ISG15 ligase, Tripartite motif-containing 25 Novel
21 TVDDPYATFV Coﬁlin-1 Novel
22 DVDPETLSY Exonuclease I Novel
23 TEFPNFKY Replication protein A 70 kDa DNA-binding subunit Novel
24 TVDPASLWEY Fascin homolog 1 Novel
25 VEIITKEF PMPCA protein Novel
26 YTELLAQVY Solute carrier family 25 member 35 Novel
27 ASDGTVRL Heterogeneous nuclear ribonucleoprotein H3 Novel
28 ASEIAVGHQY Predicted Putative solute carrier family 25 member 35 Novel
29 DENFILKH Peptidyl-prolyl cis-trans isomerase A B
30 LLYESPERY Antigen peptide transporter 1 Known immune epitope IEDB
31 NEYLNPEL Histone chaperone ASF1B Novel
32 DEAGGRFVAF Ubiquitin fusion degradation 1 like Novel
33 DEWKAIQN SERPINE1 mRNA binding protein 1 Novel
34 EEFETIERF Chromodomain-helicase-DNA-binding protein 1 B and C
35 DEKQQHIVY E3 ubiquitin-protein ligase Mdm2 D and known CLL ligand
36 AEQKKLEAA NAD(P)H dehydrogenase [quinone] 1 Novel
37 VTEAIQAVL WD repeat-containing protein 72 Novel
38 NLAEKLIGV Ral GTPase-activating protein subunit beta A (2011)
39 DEKSIITY Plectin E
40 KLLEVQILE GRIP & coiled-coil domain-containing protein 2 A (2011)
41 FGGLGGGSVR Keratin, type I cytoskeletal 19 Novel
42 GLGGGSVRFG P Keratin, type I cytoskeletal 19 Novel
43 YTSGPGSRIS Keratin, type II cytoskeletal 8 Novel
44 YTSGPGSRISS Keratin, type II cytoskeletal 8 Novel
45 VKLAKAGKN Nucleolin Found on HEK293 cells
46 ILIDWLVQV G2/mitotic-speciﬁc cyclin-B1 Known immune epitope
41 KMDASLGNLFA Protein FAM3 C F
42 DEKPLVLEm N-acetyltransferase 14 Novel
43 AEISAMLKA Pop1 Novel
44 RTLAEIAKV Non-POU domain-containing octamer-binding protein Known immune epitope IEDB
45 KIFEMGPVFTL Cytochrome c oxidase subunit II Novel
46 SEIYIHGL Ribonuclease P protein subunit p20 Novel
47 QAEFQILKA MORC family CW-type zinc ﬁnger protein 4 Novel
48 KEMPVKVEA Importin-8 isoform 2 Novel
49 TELLIRKL Histone H3.3 C Known immune epitope IEDB
50 SEYQWITSP Centrosomal protein of 78 kDa Novel
51 GSDDGTVKL 38kDa splicing factor Novel
52 TLTEEGVIKV GTP binding protein 4 Known immune epitope IEDB
53 DEVVWVRA Aspartyl-tRNA synthetase Novel
54 DEMNVKVL MYL6 protein Found in thymus
55 SEAEIFYNA Plakophilin 3 Novel
56 LTDDDLLRY 1,4-alpha-glucan-branching enzyme Known immune epitope IEDB
57 NETDILSQY Metastasis-associated protein MTA2 Novel
58 LEAHRDAPGA Serine/threonine-protein phosphatase 6 regulatory subunit 2 Novel
59 QEYSEFVKA PTPL1-associated RhoGAP 1 variant Novel
60 AEILSEMRA 2 '-5 ' oligoadenylate synthetase 3 Novel
61 ATEYKNEEY YTH domain-containing protein 1 isoform2 Known immune epitope IEDB
62 VEHKVETF 40 S ribosomal protein S7 Known immune epitope IEDB
(Continued on next page )
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Table 2. (Continued )
Peptide Protein Description
63 NEVPVKEL Leucine-rich repeat-containing protein 59-like Novel
64 DELEVIHL Ro ribonucleoprotein Known immune epitope IEDB
65 FLLGPRLVLA transmembrane emp24 domain-containing protein 10 precursor Novel
66 EEEFFYEKA BRCA2 and CDKN1 A interacting protein Novel
67 LLLDLERVL Cullin-9 Novel
68 VMAPRTLVL HLA class I histocompatibility antigen, A-2 alpha chain precursor Known immune epitope IEDB – HLA-E
binding HLA-2 leader sequence
69 PDPIRGFGS Putative poly(ADP-ribosyl) transferase Novel
70 KTDKTLVLL Proﬁlin-1 A (2011)
71 DEHEGPALY Proteasome subunit beta type-2 Known immune epitope IEDB and B
72 QMDGPLPLHY Sestrin-1 Novel
73 SSDRHLTQY Chromodomain helicase DNA binding protein 1 Novel
74 GEKRFADAA Nuclear pore complex protein Nup85 Known immune epitope IEDB
75 SLLPHETLL Pyruvate dehyrogenase phosphatase catalytic subunit 1 Novel
76 HSDPSILGY GIGYF1 protein Novel
77 YLDPRITVA DNA topoisomerase Novel
78 AVLELKNEL Protein-tyrosine kinase 2-beta Novel
79 EPAQVSLLY Ubiquitin carboxyl-terminal hydrolase 40 Novel
80 ATLVRSPGP Junction-mediating and -regulatory protein Novel
Figure 5. MEK and NFkB are associated with GEM-mediated HLA-A,B,C upregulation. For all panels n D 3 and involve HCT116 cells unless otherwise stated. a) Phosphory-
lation of ERK1/2 was increased in response to GEM in HCT116, A549 and MCF-7 cells. Representative blots from MCF-7 cells are shown. b) GEM-mediated HLA-A,B,C upre-
gulation was reduced by inhibiting ERK signalling. HCT116 cells were untreated (Un) or cultured with 100 nM GEM, C/¡ ERK inhibitor U0126 (-I ERK) at 1 mM or 10 mM
and HLA-A,B,C measured by ﬂow cytometry. n D 4. c) As b) but measuring intracellular levels of LMP2 expression by Western blot. d) Representative blot showing the
effect of U0126 on expression of LMP2 and pERK. e) Expression of p52 and RelB were measured in the cytoplasmic and nuclear fractions of HCT116 cells treated with
GEM for various durations. Representative blots are shown. Anti-b-tubulin and lamin A/C antibodies used as loading and purity controls for cytoplasmic and nuclear frac-
tions, respectively. f) HCT116 tumour cells were treated with 100 nM GEM C/¡IKK-speciﬁc NFkB inhibitor. The effect on upregulation of HLA-A,B,C at the surface of the
tumour cells was then assessed. b), c) and f) Values signiﬁcantly different from GEM-treated by one-way ANOVA with Dunnett’s test for multiple comparisons are shown.
 D p<0.05,  D p<0.01.
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those eluted from IFNg-treated cells which should have a full
immunoproteasome.
Peptides eluted from GEM-treated HCT116 cells had shifted
in character so that a higher proportion were predicted to bind
HLA-B18. This may be a consequence of an increase in shorter
peptides found after GEM-treatment, as HLA-B18 molecules
have a preference for binding shorter peptides in their binding
clefts.47 Shorter peptides may allow a broader response, as is
the case for an HLA-B18 bound 8-mer from EBV which has
been reported to initiate stronger T-cell responses to a wider
range of peptide epitopes compared to the 12-mer peptide dis-
played on HLA-B44.48 Additionally, CTLs have been shown to
lyse cells expressing HLA-B18 bound 8-mer peptides more
strongly than other peptides bound to other HLA-allotypes.49
HLA-B18 may be of particular importance in immunity. It is
associated with autoimmune diseases such as multiple sclerosis,
coeliac disease and diabetes mellitus;50-52 and multiple cancers
present with a loss or downregulation of HLA-B18 expres-
sion.53-55 Increasing the proportion of peptides that bind to
“immune-relevant” alleles may enhance immunity. However,
GEM-induced changes to antigen binding could also be detri-
mental to an immune response if the resultant peptides are des-
ignated for HLA alleles lost in loss of heterozygosity mutations.
Here, peptides would be generated but unable to be displayed
efﬁciently, potentially undermining an antigen-speciﬁc
immune response. These types of mutations are common in
cancer and may limit the use of GEM as an immune potentiator
in this disease.62,63
Altered proteasomal cleavage speciﬁcity may explain the dif-
ferences observed in peptides eluted from control or GEM-
treated cells; however, TAP-independent mechanisms may play
a role, as could changes in proteasome entry requirements or
changes to peptide trimming, transport and loading.64-66 What-
ever the true mechanism, GEM-induced changes to the confor-
mation of HLA-ligands have the potential to increase the
ability of the adaptive immune system to propagate an effective
immune response towards them.
It is reported that a discrepancy exists between the epitopes
cross-presented by DCs and those displayed on tumour cells.67
GEM may overcome this by inducing immunoproteasomes in
cancer cells and shifting the peptides displayed on HLA class I
molecules to be more similar to those generated and cross-pre-
sented by APCs. Interestingly, in the above study involving
NY-ESO-1, the efﬁciently cross-presented, immunoproteaso-
mally generated NY-ESO-188-96 peptide was HLA-B
18
restricted, while the non-immunogenic, NY-ESO-1157-165, was
HLA-A02 restricted.
Numerous peptides were exclusively found after GEM treat-
ment and not on control cells, raising the possibility of using
some of these novel, GEM-inducible antigens in future immu-
notherapy-GEM combinations. Some GEM-inducible peptides
were derived from tumour-associated proteins, suggesting that
GEM-treatment may reveal tumour antigens to immune cells.
There were also a number of novel peptides from proteins inti-
mately associated with the DNA-damage response (DDR) and
these may represent a signal to the immune system further to
the well-known innate signals induced by DNA-damage, such
as increased expression of CD95 or NKG2D ligands. Many of
the peptides found only on GEM-treated cells have previously
been observed on other cell types, including: patented immuno-
gens and tumour-associated peptides. The GEM-inducible pep-
tide, ILIDWLVQV, has been identiﬁed by reverse immunology
and shown to elicit spontaneous T-cell reactivity in blood from
cancer patients and healthy donors. Additionally, there were
GEM-inducible peptides previously described as “unique” to
HIV MN-1-infected human T-cells; an interesting ﬁnding in
the context of the work presented here, as GEM-treatment and
viral-infection both induce immunoproteasomes and provide
danger signals to immune cells. Further to those previously
reported immunogens, the 53 novel peptides found in response
to GEM represent new HLA-ligands that may be chemother-
apy-speciﬁc and novel epitopes for cytotoxic T-cells.
A primary function of the adaptive immune response is to
protect the integrity of the genome and as such the antigenic
targets of T-cells are often evidence of some defect in the DNA
of a cell, the most pertinent example of this in cancer being the
“targetability” of neoantigens. Neoantigens, tumour-associated
antigens, and antigens corresponding to other forms of DNA
damage have consistently been shown to elicit robust and effec-
tive CD8C T-cell responses. In the present study, many of the
GEM-inducible novel peptides appearing on HLA-A,B,C were
linked to the DDR, which may suggest that self-antigens from
DDR proteins are immunogenic. A theory conceptually advan-
tageous as it would allow rapid responses by a less clonally
diverse pool of T-cells against cells harbouring DNA damage,
and plausible, given that these antigens will often be perceived
by the immune system under inﬂammatory conditions and the
existence of T-cells speciﬁc to DDR-related protein antigens
such as MDM2 and TOPO1 in the periphery.68,69 If GEM is
providing a mechanism for these danger signals to be displayed
on tumour cells then this helps explain the reported synergy
between the drug and immunotherapy. Renovating the pepti-
dome in this way may be a prime strategy to reengage immune
responses against tumours and could also play a role in autoim-
mune disease and toxicities associated with GEM.
GEM-mediated cellular damage, genomic or otherwise, may
generate peptides normally only seen on diseased or damaged cells
making these cells targetable by the immune system. This concept
increases understanding about the improved efﬁcacy of chemo-
therapies in immunocompetent individuals and helps to identify
mechanisms by which GEM has been shown to alter the antigen-
speciﬁcity of primed CD8C T-cells towards subdominant epitopes.
GEMmay not be unique in this action but understanding the rela-
tionship between drug treatment and altered immunopeptidome
may be important in boosting T-cell responses to cancer and poses
questions as to which antigens should be chosen to combine with
chemotherapy. This work suggests a rationale for combining
GEM-treatment with immunotherapies, such as anti-PD-1, as
increasing the antigenicity of the tumour will render it more sus-
ceptible to antigen-speciﬁc CD8C T-cells that may be uncon-
strained by checkpoint blockade therapy.
Methods
Tumour cell lines
The human cancer cell lines: A549 (lung), HCT116 (colon) and
MCF7 (breast) (all Public Health England, Porton down, UK),
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were grown in DMEM (Sigma-Aldrich, Dorset, UK) medium
supplemented with 10% foetal bovine serum (Invitrogen, Pais-
ley, UK) and 1% penicillin/streptomycin (Sigma). All cell lines
were incubated in a humidiﬁed atmosphere with 5% CO2 in air
at 37 C. For in vitro experiments, cells were seeded at 1 £ 105
cells/ml and allowed to attach overnight before addition of
experimental reagents. All experiments represent 24 hour treat-
ment of cells with 100 nM GEM unless otherwise stated.
Drugs, cytokines and inhibitors
GEM, OXP, CPM (all Sigma) and IFNg (R & D biosystems,
Abingdon, UK) were reconstituted in phosphate buffered saline
(PBS) (Sigma). IC25 values used for GEM, OXP and CPM were:
100 nM, 500 nM and 1mM, respectively. Cell signalling was
inhibited by U0126 (New England Biolabs (NEB), Hitchin,
UK) and NFkB by IKK-16 (Selleck Chemicals).
Flow cytometry
Cells were stained with HLA-A,B,C-FITC (Becton Dickinson
(BD), Oxford, UK) using manufacturer’s instructions prior to
analysing with LSRII ﬂow cytometer (BD Biosciences).
Immunoblotting
Cells were solubilised in lysis buffer (NEB) and resolved by tris-
glycine electrophoresis. Following transfer of proteins onto
nitrocellulose membranes (ThermoFisher Scientiﬁc, Dartford,
UK), staining was performed with primary and then horserad-
ish peroxidase (HRP)-conjugated anti-species secondary anti-
bodies. Primary antibodies used were speciﬁc for: proteasome
subunits a2, b1 and b2, b5 (all Enzo Life Sciences, Exeter, UK),
b2 m (Abcam, Cambridge, UK), HLA-A, B and C (all Santa-
Cruz Biotechnologies, California, USA), LMP2 (b1i), LMP7
(b5i) and MECL-1 (b2i) (all Abcam), pERK, tERK, RelB, p50,
p52, p65 (all NEB). Bands were visualised on HyperﬁlmTM ECL
(GE Healthcare, Buckinghamshire, UK) using SuperSignalTM
West Pico chemiluminescent substrate (Thermo). The house-
keeping protein, glyceraldehyde 3-phosphate dehydrogenase
(GAPDH) (NEB) was used as a loading control.
Separation of Nuclear and Cytoplasmic Fractions
Cell lysates were separated into nuclear and cytoplasmic frac-
tions using NE-PER Nuclear and Cytoplasmic Extraction
reagents (Thermo) and following manufacturer’s instructions.
Brieﬂy, Cytoplasmic Reagent (CER) I was added to cells before
vortexing vigorously and addition of CER II. Cells were then
centrifuged at 16000 g for 5 minutes and the supernatant (cyto-
plasmic extract) isolated and stored. The cell pellets were resus-
pended in Nuclear Extraction Reagent and incubated on ice for
40 minutes with vigorous vortexing at regular intervals. The
resulting lysate was then centrifuged at 16000 g for 10 minutes
and the supernatant (nuclear extract) stored at -80oC. After
separation, cytoplasmic and nuclear fractions were treated as
total cellular lysates in the previous section. Lamin A/C (NEB)
and b-tubulin (NEB) were used to determine the quality of the
separation and as loading controls for the nuclear and cyto-
plasmic protein fractions, respectively.
Real-time reverse transcriptase polymerase chain reaction
High purity RNA was isolated from HCT116 cells with the Qia-
gen RNA extraction mini-prep kit (Qiagen, Manchester, UK)
using manufacturer’s instructions. This was converted to
cDNA by reverse transcription using precision RT all-in-one
mix (Primer Design Ltd, Southampton, UK). Gene expression
of b2 m was then measured by qPCR, using QuantiTect Sybr
Green-based qPCR primers (Qiagen, Manchester, UK).
Approximately 40 ng cDNA (4 ml), 1 ml QuantiTect primer
and 10 ml SsoFastTM EvaGreen Supermix (Bio-rad, Hertford-
shire, UK) were added to the qPCR reaction mix. 18 S ribo-
somal RNA was used as the reference gene.
Illumina microarray
RNA was isolated from HCT116 cells using the Qiagen mini-kit
protocol as before. Microarrays were performed by Dr Jayne
Dennis at the SGUL Biomics Centre as described previously.70
Transfections
Tumour cells were transfected with a human b2 m
(NM_004048) expressing, pCMV6-XL5 plasmid (OriGene,
Herford, Germany) using Lipofectamine LTX (HCT116 cells)
or Lipofectamine 3000 (A549 and MCF-7 cells) (Invitogen)
and following manufacturer’s instructions. Brieﬂy, DNA-lipid
complexes were added to cells before incubating for 48 hours at
37oC and 5% CO2 in a humidiﬁed atmosphere. Expression of
HLA-A,B,C at the cell surface was then determined by ﬂow
cytometry. Cells “mock transfected” with a non-encoding plas-
mid were used as a negative control
HLA ligand elution and sequencing
HCT116 cells were lysed in buffer containing PBS, 0.6% CHAPS,
and complete protease inhibitor (Roche). Following centrifuga-
tion to remove debris supernatant was applied on afﬁnity col-
umns overnight. Columns were prepared by coupling W6/32
antibodies to CNBr-activated Sepharose (GE Healthcare) (1 mg
antibody/40 mg Sepharose). On the second day the columns
were eluted in 8 steps using 0.2% TFA. Filtration of the eluate
through a 10 kDa ﬁlter (Merck Millipore, Darmstadt, Germany)
yielded the HLA ligands in solution. The ﬁltrate was desalted
with C18 ZipTips (Merck) and subsequently concentrated using
a vacuum centrifuge (Bachofer, M€unchen, Germany). Sample
volume was adjusted for measurement by adding 1% ACN/
0.05% TFA (v/v). With an injection volume of 5 ml HLA ligands
were loaded (100 mm x 2 cm, C18, 5 mm, 100 A

) and separated
(50 mm x 25 cm, C18, 3 mm, 100 A

) on Acclaim Pepmap100 col-
umns (Dionex, Sunnyvale, CA) using an Ultimate 3000
RLSCnano uHPLC system (Dionex). A gradient ranging from
2.4-32% of ACN/H2O with 0.1% formic acid was used to elute
the peptides from the columns over 90 min at a ﬂow rate of 300
nl/min. Online electrospray ionization (ESI) was followed by
tandem MS analysis in a LTQ Orbitrap XL instrument (Thermo
Fisher Scientiﬁc, Bremen, Germany). Survey scans were acquired
in the Orbitrap mass analyser with a resolution of 60.000 and a
mass range of 400 to 650 m/z. Peptides with a charge state other
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than 2C or 3C were rejected from fragmentation. Fragment
mass spectra of the 5 most intense ions of each scan cycle were
recorded in the linear ion trap (top5 CID). Normalized collision
energy of 35%, activation time of 30 ms and isolation width of 2
m/z was utilized for fragment mass analysis. Dynamic exclusion
was set to 1s. The RAW ﬁles were processed against the human
proteome as comprised in the Swiss-Prot database (www.uni
prot.org, status: Dec12th, 2012; 20.225 reviewed sequences con-
tained) using MASCOT server version 2.3.04 (Matrix Science,
Boston, MA) and Proteome Discoverer 1.4 (Thermo). Oxida-
tion of methionine was allowed as dynamic peptide modiﬁca-
tion. A mass tolerance of 5 ppm or 0.5 Da was allowed for
parent and fragment masses respectively. Filtering parameters
were set to a Mascot Score<20, search engine rank D 1, peptide
length of 8–12 AA, achieving a false discovery rate (FDR) of 5%
as determined by an inverse decoy database search.
Peptide sequence analysis
Peptides was stratiﬁed into two groups: those sequences that
were unique to control HCT116 cells and those that were
unique to GEM-treated HCT116 cells. These peptide groups
were then subjected to various tests, including analysis of:
length, C-terminal amino acid, predicted HLA-allele binding
and predicted immunogenicity. The length and C-terminal
amino acid of each peptide was determined manually. MHC
class I binding predictions were made with IEDB Analysis
Resource (http://tools.immuneepitope.org/mhci/) and SYFPEI-
THI Epitope Prediction (http://www.syfpeithi.de/bin/
MHCServer.dll/EpitopePrediction.htm) using the HLA-alleles
HLA-A01:01, HLA-A02:01, HLA-B18:01 and HLA-B45:01.
Predicted Immunogenicity of the peptides was determined
using a model, IEDB Analysis Resource (http://tools.iedb.org/
immunogenicity/), where the peptides were analysed for the
presence of particular immunogenicity-associated amino acids
at speciﬁc positions in the peptide sequence.33 N.B. Due to a
technical issue with the peptide length data in one of the three
peptide elution experiments, this data was removed from the
analysis of Fig. 3a and replaced by peptide length data from a
small pilot study.
Proteasome isolation
Proteasomes were puriﬁed using the Enzo Protein Puriﬁcation
Kit (Enzo Life Sciences, Exeter, UK) and following manufac-
turer’s instructions. Brieﬂy, cells were lysed for 15 minutes on
ice before centrifuging at high speed to clear the supernatant. A
sample of this crude lysate was put aside for analysis and pro-
teasome puriﬁcation matrix (agarose immobilised anti-protea-
some subunit-a4 antibodies) added to the remaining
supernatant (25 ml matrix/100 mg protein). After incubation
overnight, the matrix was isolated by centrifugation for 30 sec-
onds at 5000 g and the supernatant (unbound fraction) set
aside for analysis. Proteasomes were eluted from the matrix by
the addition of LDS and boiling for 10 minutes.
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